Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, PR China.
Free Radic Res. 2011 Jun;45(6):662-71. doi: 10.3109/10715762.2011.564167. Epub 2011 Mar 11.
Advanced oxidation protein products (AOPP) as a biomarker of oxidative stress has been demonstrated in chronic kidney disease (CKD) patients; however, current methods to detect the accumulation of AOPP in serum and in tissues are limited and unreliable. This study generated a monoclonal antibody (mAb) designated 3F2, that reacts specifically with hypochlorous acid (HOCl)-modified proteins, but not with the native forms or with other types of oxidative modifications. Notably, mAb 3F2 recognizes the AOPP deposited in renal tissues of AOPP-treated rats and of patients with different kinds of CKD. Moreover, this mAb can almost completely inhibit the production of reactive oxygen species in RAW264.7 cells induced by AOPP (p < 0.001). In conclusion, mAb 3F2 can be used to detect AOPP specifically in serum and in tissues, and this antibody can potentially provide an important tool and new insight into research on diseases related to oxidative stress.
先进氧化蛋白产物（AOPP）作为氧化应激的生物标志物，已在慢性肾脏病（CKD）患者中得到证实；然而，目前检测血清和组织中 AOPP 积累的方法有限且不可靠。本研究产生了一种单克隆抗体（mAb），命名为 3F2，它特异性地与次氯酸（HOCl）修饰的蛋白质反应，而不与天然形式或其他类型的氧化修饰反应。值得注意的是，mAb 3F2 识别在 AOPP 处理的大鼠和不同类型 CKD 患者的肾脏组织中沉积的 AOPP。此外，该 mAb 几乎可以完全抑制 AOPP 诱导的 RAW264.7 细胞中活性氧的产生（p < 0.001）。总之，mAb 3F2 可特异性地用于检测血清和组织中的 AOPP，该抗体可能为与氧化应激相关疾病的研究提供重要工具和新的见解。
